Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

This study is ongoing, but not recruiting participants.

Study NCT00274742 Information provided by Micromet GmbH

First Received: January 10, 2006 Last Updated: October 5, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	December 2011
Primary Completion Date:	August 2011 (Final data collection date for primary outcome measure)